Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

129
Delayed Quote. Delayed Nyse - 11/26 11:55:18 am
59.5 USD   +0.27%
1d ago MERCK : Announces Increased Quarterly Dividend
2d ago Bayer explores possible sale of diabetes device unit - Bloomberg
2d ago MERCK : Iowa firm sign Ebola vaccine licensing deal
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
React to this article
Latest news on MERCK & CO., INC.
15m ago MERCK : Findings from Merck & Company Broaden Understanding of Heart Failure (Co..
1d ago MERCK : Announces Increased Quarterly Dividend
2d ago Bayer explores possible sale of diabetes device unit - Bloomberg
2d ago MERCK : Iowa firm sign Ebola vaccine licensing deal
2d ago Merck buys rights to NewLink's experimental Ebola vaccine
2d agoDJBristol-Myers, Five Prime to Collaborate on Immunotherapy
2d ago MERCK : Submits New Drug Application to the Japanese Pharmaceuticals and Medical..
2d ago MERCK : and NewLink Genetics Enter Into Licensing and Collaboration Agreement fo..
6d ago MERCK : Dow Movers: MRK, MCD
7d ago MERCK : New Findings on Vaccines Described by Investigators at Merck & Company (..
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF